Status:
TERMINATED
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Cardiac Surgery Requiring Cardiopulmonary Bypass
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Post-operative bleeding according to pre-defined criteria for critical bleeding
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT00154427
Start Date
August 1 2004
End Date
November 1 2007
Last Update
January 12 2017
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35235
2
Novo Nordisk Investigational Site
Tucson, Arizona, United States, 85714
3
Novo Nordisk Investigational Site
San Francisco, California, United States, 94115
4
Novo Nordisk Investigational Site
Denver, Colorado, United States, 80262